Shots:

• The P-III program consists of two trials (ISABELA 1 & 2) assessing ziritaxesta (200/ 600mg- qd) + SOC vs PBO + SOC in ~1500 patients with IPF. The 1EPs of the study decline in forced vital capacity until 52wks.
• The termination of the study is based IDMC’s recommendation following a regular review of unblinded data- which concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies
• Ziritaxestat is an investigational autotaxin inhibitor. Additionally- all clinical trials with ziritaxestat includes the long-term extension of P-IIa NOVESA trial in systemic sclerosis will be discontinued

 ­ Ref: GlobeNewswire | Image: Galapagos